Stifel has initiated coverage on Inozyme Pharma (INZY), highlighting the potential of its lead candidate, INZ-701, an enzyme replacement therapy (ERT) for rare diseases. The analyst believes the drug has pipeline-in-a-product potential and forecasts a Buy rating with a price target of $16.